vs
CytomX Therapeutics, Inc.（CTMX）与First Bancorp, Inc（FNLC）财务数据对比。点击上方公司名可切换其他公司
First Bancorp, Inc的季度营收约是CytomX Therapeutics, Inc.的1.4倍（$25.8M vs $18.7M），First Bancorp, Inc净利率更高（39.4% vs -0.8%，领先40.2%），First Bancorp, Inc同比增速更快（17.5% vs -25.7%），First Bancorp, Inc自由现金流更多（$34.6M vs $-15.8M），过去两年First Bancorp, Inc的营收复合增速更高（18.1% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
第一银行公司（First Bancorp, Inc）是一家银行控股公司，其核心业务通过总部位于康涅狄格州斯坦福的爱国者国家银行（Patriot Bank NA）开展，相关 banking 业务也以PNBK代码在纳斯达克挂牌交易。
CTMX vs FNLC — 直观对比
营收规模更大
FNLC
是对方的1.4倍
$18.7M
营收增速更快
FNLC
高出43.2%
-25.7%
净利率更高
FNLC
高出40.2%
-0.8%
自由现金流更多
FNLC
多$50.4M
$-15.8M
两年增速更快
FNLC
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $25.8M |
| 净利润 | $-154.0K | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 48.1% |
| 净利率 | -0.8% | 39.4% |
| 营收同比 | -25.7% | 17.5% |
| 净利润同比 | 97.6% | 39.7% |
| 每股收益（稀释后） | — | $0.91 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXFNLC
| Q4 25 | — | $25.8M | ||
| Q3 25 | — | $24.5M | ||
| Q2 25 | $18.7M | $22.5M | ||
| Q1 25 | $50.9M | $21.8M | ||
| Q4 24 | $38.1M | $22.0M | ||
| Q3 24 | $33.4M | $20.5M | ||
| Q2 24 | $25.1M | $19.2M | ||
| Q1 24 | $41.5M | $18.5M |
净利润CTMXFNLC
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $9.1M | ||
| Q2 25 | $-154.0K | $8.1M | ||
| Q1 25 | $23.5M | $7.1M | ||
| Q4 24 | $18.9M | $7.3M | ||
| Q3 24 | $5.7M | $7.6M | ||
| Q2 24 | $-6.5M | $6.2M | ||
| Q1 24 | $13.8M | $6.0M |
营业利润率CTMXFNLC
| Q4 25 | — | 48.1% | ||
| Q3 25 | — | 45.2% | ||
| Q2 25 | -6.9% | 43.7% | ||
| Q1 25 | 44.4% | 39.3% | ||
| Q4 24 | 46.4% | 39.5% | ||
| Q3 24 | 12.3% | 44.6% | ||
| Q2 24 | -33.7% | 38.8% | ||
| Q1 24 | 28.1% | 39.3% |
净利率CTMXFNLC
| Q4 25 | — | 39.4% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | -0.8% | 35.8% | ||
| Q1 25 | 46.2% | 32.5% | ||
| Q4 24 | 49.6% | 33.1% | ||
| Q3 24 | 17.2% | 36.9% | ||
| Q2 24 | -26.0% | 32.1% | ||
| Q1 24 | 33.3% | 32.5% |
每股收益（稀释后）CTMXFNLC
| Q4 25 | — | $0.91 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.72 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.66 | ||
| Q3 24 | — | $0.68 | ||
| Q2 24 | — | $0.55 | ||
| Q1 24 | — | $0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | — |
| 总债务越低越好 | — | $95.5M |
| 股东权益账面价值 | $119.9M | $283.1M |
| 总资产 | $175.1M | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资CTMXFNLC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
总债务CTMXFNLC
| Q4 25 | — | $95.5M | ||
| Q3 25 | — | $95.5M | ||
| Q2 25 | — | $95.0M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | $95.0M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $70.0M | ||
| Q1 24 | — | $70.0M |
股东权益CTMXFNLC
| Q4 25 | — | $283.1M | ||
| Q3 25 | — | $274.6M | ||
| Q2 25 | $119.9M | $265.5M | ||
| Q1 25 | $25.0M | $259.7M | ||
| Q4 24 | $-456.0K | $252.5M | ||
| Q3 24 | $-23.5M | $256.8M | ||
| Q2 24 | $-31.2M | $244.7M | ||
| Q1 24 | $-31.7M | $242.6M |
总资产CTMXFNLC
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $175.1M | $3.2B | ||
| Q1 25 | $98.5M | $3.2B | ||
| Q4 24 | $120.5M | $3.2B | ||
| Q3 24 | $139.0M | $3.1B | ||
| Q2 24 | $159.2M | $3.1B | ||
| Q1 24 | $184.7M | $3.0B |
负债/权益比CTMXFNLC
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $37.8M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $34.6M |
| 自由现金流率自由现金流/营收 | -84.6% | 133.9% |
| 资本支出强度资本支出/营收 | 0.1% | 12.5% |
| 现金转化率经营现金流/净利润 | — | 3.72× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $55.3M |
8季度趋势，按日历期对齐
经营现金流CTMXFNLC
| Q4 25 | — | $37.8M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | $-15.8M | $7.4M | ||
| Q1 25 | $-21.0M | $2.2M | ||
| Q4 24 | $-19.9M | $26.0M | ||
| Q3 24 | $-20.7M | $9.8M | ||
| Q2 24 | $-19.5M | $6.4M | ||
| Q1 24 | $-26.0M | $-1.5M |
自由现金流CTMXFNLC
| Q4 25 | — | $34.6M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $-15.8M | $7.2M | ||
| Q1 25 | $-21.2M | $828.0K | ||
| Q4 24 | $-20.0M | $24.6M | ||
| Q3 24 | $-20.7M | $9.6M | ||
| Q2 24 | $-19.6M | $6.3M | ||
| Q1 24 | $-26.2M | $-1.8M |
自由现金流率CTMXFNLC
| Q4 25 | — | 133.9% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | -84.6% | 32.1% | ||
| Q1 25 | -41.6% | 3.8% | ||
| Q4 24 | -52.5% | 111.7% | ||
| Q3 24 | -62.1% | 47.0% | ||
| Q2 24 | -78.2% | 32.9% | ||
| Q1 24 | -63.1% | -9.8% |
资本支出强度CTMXFNLC
| Q4 25 | — | 12.5% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 0.1% | 0.6% | ||
| Q1 25 | 0.2% | 6.2% | ||
| Q4 24 | 0.2% | 6.7% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 0.3% | 1.8% |
现金转化率CTMXFNLC
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | -0.89× | 0.31× | ||
| Q4 24 | -1.05× | 3.58× | ||
| Q3 24 | -3.61× | 1.29× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | -1.89× | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FNLC
暂无分部数据
